# Genetic pleiotropy differentially linking brain variation to cannabis use and cannabis use disorder > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/genetic-pleiotropy-differentially-linking-brain-variation-to-cannabis-use-and-cannabis-use-disorder/ > **Published:** 2026-07-30T18:29:43-04:00 | **Last Modified / Clinically Audited:** 2026-09-09T10:02:13-04:00 > **Clinical Summary:** New genetic research reveals distinct cannabis use disorder pathways involving ENPP6, opening precision medicine approaches for CUD prevention. --- ✦ New CED Clinical Relevance #62 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchNeurologyMental HealthTHCSafetyPolicyPain Why This Matters Identifying shared genetic factors between [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) and [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) could help clinicians better predict which patients are at highest risk for problematic use patterns and tailor prevention or early intervention strategies accordingly. Understanding the molecular mechanisms, particularly genes like ENPP6 involved in brain metabolism, opens pathways for potential therapeutic targets to treat [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) or mitigate its neurobiological consequences. This genetic insight may enable more personalized clinical approaches rather than one-size-fits-all treatment recommendations for patients struggling with [cannabis dependence](https://cedclinic.com/ptsd-cannabis-dependence-veterans-social-support/). Clinical Summary This genetic study identifies shared molecular pathways between brain structure variation and both [recreational cannabis](https://cedclinic.com/tennessee-medical-cannabis-program-debate-2026/) use and [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) disorder, revealing that certain genetic factors predispose individuals to cannabis consumption while others specifically increase vulnerability to developing addiction. The research employed drug-repurposing analyses to pinpoint nine molecular compounds involved in these pathways, with ENPP6 (a lipid metabolism enzyme) emerging as particularly significant in differentiating casual use from disorder development. These findings suggest that genetic screening or biomarker identification based on ENPP6 and related pathways could eventually help clinicians identify patients at higher risk for [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) before or early in their use trajectory. Understanding these molecular mechanisms also opens potential therapeutic avenues, as drugs targeting these pathways might reduce addiction liability or support treatment. For clinicians, this research underscores that [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) disorder has identifiable biological substrates distinct from recreational use, potentially informing more personalized [risk assessment](https://cedclinic.com/ethical-legal-dilemmas-cannabis-use/) and counseling during initial cannabis use discussions with patients. Dr. Caplan’s Take “This genetic pleiotropy study is interesting foundational work that maps shared biological pathways between brain structure and cannabis use patterns, but we need to be cautious about how we interpret it clinically—identifying a genetic signal isn’t the same as understanding causation or predicting who will develop problematic use. The compounds they’ve flagged, like ENPP6, are worth monitoring in future research, but we’re still years away from having actionable genetic tests or interventions based on this work.” Clinical Perspective 💉 This genetic pleiotropy study identifying shared molecular pathways between brain structure variation and cannabis use disorder, particularly implicating ENPP6 in lipid metabolism, suggests that individual susceptibility to problematic cannabis use may have partly distinct biological underpinnings from casual use itself—a distinction often obscured in clinical encounters. While the findings are mechanistically interesting and could eventually inform risk stratification, the translation from genomic associations to clinical utility remains uncertain, and the study cannot establish causation or account for the substantial environmental, psychosocial, and developmental factors that drive cannabis use disorder in real-world populations. The identified compounds warrant further investigation as potential therapeutic targets, but clinicians should recognize that genetic risk factors operate alongside modifiable drivers such as age of initiation, concurrent mental health conditions, and social context. For now, this research reinforces that cannabis use disorder is biologically complex rather than purely volitional, which may help reduce stigma 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Genetic%20pleiotropy%20differentially%20linking%20brain%20variation%20to%20cannabis%20use%20and%20cannabis%20use%20disorder%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71791)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71791)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Genetic%20pleiotropy%20differentially%20linking%20brain%20variation%20to%20cannabis%20use%20and%20cannabis%20use%20disorder%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71791)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.nature.com/articles/s41386-026-02506-y](https://www.nature.com/articles/s41386-026-02506-y) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).